Michael Taylor: TE faces funding challenges over Chinese ties

Michael Taylor: TE faces funding challenges over Chinese ties
TE seen as funding risk amid China ties

Michael Taylor, co-founder / portfolio manager at Agora Trading, observes that TE is seen as a Chinese solar company operating as an American firm, which he believes makes it difficult for the company to secure funding due to its perceived Chinese origins.

Taylor adds that there is significant short interest of around 30% or more of the float, suggesting market skepticism about TE's prospects. However, he expresses a positive outlook and believes TE could potentially overcome these challenges.

Taylor has previously flagged AQRT’s Phase 2 Vitiligo study targeting a $1 billion market as a potential catalyst to double the firm’s total addressable market, according to a recent article (link). He also noted a $2 billion preferred convertible agreement between Summit Therapeutics and AstraZeneca aimed at advancing lung cancer therapies (link). These comments reflect Taylor’s ongoing coverage of significant fundraising and partnership activities within the healthcare and biotech sectors.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.